Adults: The recommended dose of MOLNUPAC is 800 mg (four 200mg capsules or two 400mg capsules) taken orally every 12 hours for 5 days.
The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established. MOLNUPAC 200/MOLNUPAC 400 should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
Missed dose: If the patient misses a dose of MOLNUPAC 200/MOLNUPAC 400 within 10 hours of the time it is usually taken, the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.
Special populations: Elderly: No dose adjustment of MOLNUPAC 200/MOLNUPAC 400 is required based on age.
Renal impairment: No dose adjustment is required for patients with renal impairment.
Hepatic impairment: No dose adjustment is required for patients with hepatic impairment.
Paediatric population: The safety and efficacy of MOLNUPAC 200/MOLNUPAC 400 in patients below 18 years of age have not been established. No data are available.
METHOD OF ADMINISTRATION: For oral use.
MOLNUPAC 200/MOLNUPAC 400 capsules can be taken with or without food.
The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed.